Novasecta

The Novasecta Team are looking forward to a fantastic year ahead with our wonderful clients and partners. Happy New Year to all! 🥳

As the year comes to a close, we’d like to thank our clients and partners for your continued support and wish you all an enjoyable holiday period! 🎄 🥂

Establishing a clear TA focus, prioritising R&D productivity and maintaining profitable commercialisation are core to the success of leading MidPharmas.   In our new annual European MidPharma report, we delve into these success factors for sustainable and profitable growth, and examine the 2023 performance of 52 European-headquartered MidPharmas.   Download your copy today 👇 https://lnkd.in/eU3PAHdg   #Pharma #Pharmaceuticals #PharmaceuticalStrategy #Biopharma #Strategy #Consulting #MidPharma #StrategicFocus #RandDProductivity #Profitability

📣The Novasecta European MidPharma Report 2024 The ninth edition of our annual European MidPharma Report is here. This year’s report explores how the most successful MidPharmas are delivering growth and impressive returns through common success drivers: 🔎 Establish a therapeutic area focus 💊 Prioritise R&D productivity 💰 Maintain profitable commercialisation Download your free copy here: https://lnkd.in/eU3PAHdg #MidPharmas #Pharma #WhitePaper #RnD #Strategy #OperationalExcellence #Productivity #Strategy #Consulting

🏭 Organisational complexity and scale are two sides of the same coin. In a quest for scale, Big Pharma companies have built large, diverse portfolios that span multiple therapeutic areas and technologies. But this comes with its own set of challenges. 💊 Portfolio diversity leads to inevitable organisational complexity, requiring leaders to think more proactively about decision-making effectiveness, capability-building, and role clarity. 🌟 In this white paper, we explore how organisational complexity is driven by scale and portfolio diversity, and illustrate the need for operational excellence when pursuing sustainable growth. Read the full white paper on our website: https://lnkd.in/eTuUy_Gq #pharma #biotech #bigpharma #pharmaceutical #organisationalcomplexity #businessconsulting #strategy #operatingmodel

Most pharma R&D organisations are defined and measured by how well they deliver new product innovation, which is a high risk, high return endeavour. Yet such companies almost always have a second, highly important and sometimes underappreciated role: creating value from on market products. This article, published in MedNous, analyses the performance of these companies in the context of new product and on-market product innovation, and demonstrates that success in on-market product innovation provides companies with the profit margins to additionally invest in new product innovation. © 2023 Evernow Publishing Ltd Reprinted with permission from MedNous, April 2023 (www.mednous.com) For further insights into Europe’s MidPharmas, we examine this microcosm of the global industry and analyse how these companies thrive in our annual European MidPharma Report. Find this and other articles on our website: https://lnkd.in/dJGwi5Fc #pharma #biotech #strategy #pharmaceutical #researchanddevelopment

How can Medical Affairs be successfully leveraged? Pharmaceutical companies face complex challenges that the Medical Affairs function is uniquely positioned to help overcome. In this white paper, we examine how Medical Affairs can be successfully leveraged, with an emphasis on: - The challenges facing pharma that Medical Affairs is well-positioned to overcome - The unique value of Medical Affairs - Imperatives for future Medical Affairs impact Click here to find out more: https://lnkd.in/dH4VuuJ8 #MedicalAffairs #MedAffairs #Pharma #Pharmaceuticals #Biotech #Biopharma #Strategy #Consulting

Coming Soon! The ninth edition of our annual European MidPharma Report is coming very soon. In this latest edition we will assess the 2023 performance of European MidPharmas and will describe the key factors for their continued success. Keep an eye out for our newsletter and LinkedIn for updates. If you would like to be sent a copy, please don’t hesitate to contact us. Click here to see last year’s report: https://lnkd.in/ddGAwFZs #MidPharma #WhitePaper #RnD #Strategy #OperationalExcellence

In last month's newsletter we shared insights on how successful pharma companies focus on cross-functional collaboration. From a Market Access perspective, this means being a strategic partner across R&D and Commercial Functions. We enable our clients to create clarity on the role of the Market Access function and ensure consistent timing and implementation of key market access activities across brands. Find out more by reading our client story here: https://lnkd.in/edvyg_qj

⏲ Coming Soon! 📑 In our latest annual European MidPharma Report, we will take an in-depth look at this important pharmaceutical industry sector and describe the ingredients for MidPharmas' continued success. Keep an eye out on our LinkedIn and newsletter for updates. If you would like to be sent a copy, please don't hesitate to contact us. Details can be found on our website: www.novasecta.com